01—Abstract
Summary
Summary of the 8-K filed September 3, 2024. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. filed a Current Report on Form 8-K to incorporate by reference information from its previous filings, specifically to reflect a change in its operating segment reporting structure.
The company has recasted its historical financial segment information to align with a reorganization announced in the first quarter of fiscal year 2024. This reorganization moved the cell analysis business from the 'Life Sciences and Applied Markets' segment to the 'Diagnostics and Genomics' segment. This 8-K filing serves to update the presentation of segment data within previously filed documents, primarily the Annual Report on Form 10-K for the year ended October 31, 2023.
Investors should note that this report does not contain new financial information or updates on subsequent events beyond the segment recasting. For the most current financial performance and events, investors should refer to Agilent's most recent Form 10-Q filing for the quarter ended July 31, 2024.
02—Key points
Key Highlights
- Agilent Technologies is filing an 8-K to reflect updated segment reporting.
- The company has moved its cell analysis business from 'Life Sciences and Applied Markets' to 'Diagnostics and Genomics'.
- This change was announced in Q1 FY2024 and aims to strengthen growth opportunities for both segments.
- Historical financial segment information has been recast to conform to the new structure.
- This filing recasts specific items in the Form 10-K for the year ended October 31, 2023.
- The report does NOT include any new financial information or updates on events subsequent to the Form 10-K filing, other than segment adjustments.
- Investors should consult the latest Form 10-Q for current financial performance and updates.
03—Questions
Frequently Asked Questions
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to incorporate by reference and present recasted historical segment financial information that reflects a previously announced change in Agilent's operating segments. Specifically, the cell analysis business was moved from the Life Sciences and Applied Markets segment to the Diagnostics and Genomics segment.
Does this filing contain any new financial results or performance updates?
No, this filing does not contain any new financial results or updates on events occurring after the filing of the Annual Report on Form 10-K for the year ended October 31, 2023. It solely addresses the restatement of historical segment reporting due to a business structure change.
Where can I find the most recent financial information and updates for Agilent Technologies?
For the most current financial performance, events, and updates, investors should refer to Agilent's Quarterly Report on Form 10-Q for the quarterly period ended July 31, 2024, and other subsequent filings with the Securities and Exchange Commission.
What is the significance of recasting historical segment information?
Recasting historical segment information ensures that financial comparisons over time are consistent and accurately reflect the company's current reporting structure. This allows investors to better analyze trends and performance within each segment as they are now defined.
04—Continue